Knostic Wins 2024 Black Hat Startup Spotlight Competitionby Lilu Anderson 08.08.2024Knostic emerges victorious at the 2024 Black Hat Startup Spotlight Competition, showcasing its innovative approach to LLM access control.
Taco Bell AI Drive-Thrus: Revolutionizing Fast Food by Year’s Endby Lilu Anderson 08.08.2024Taco Bell’s AI drive-thrus aim to enhance customer experience and efficiency, potentially transforming fast food by year’s end.
DOGE Price Prediction: Will it Break $0.09 or Rebound?by John Darbie 08.08.2024Analyzing the recent 1.40% increase in DOGE, what's next for its price? Will it break $0.09 or rebound to $0.1?
Key Dogecoin Price Indicators After Shiba Inu’s 25% Lossby John Darbie 08.08.2024Analyzing Dogecoin's price indicators after it mirrors Shiba Inu's 25% losses. Key technical insights suggest more volatility ahead.
BTC Price Prediction: What to Expect on 08.08.2024by Terry Bingman 08.08.2024Predict Bitcoin's price for the next 72 hours using historical data, key indicators, and market sentiment. Strategic insights by Terry ...
Wolverine World Wide Exceeds Q2 Expectations Despite Revenue Dipby Mark Eisenberg 08.08.2024Wolverine World Wide beats Q2 earnings estimates with $425.2 million revenue, despite a 17.4% YoY decline.
AI Transforming Education: Local Schools to Implement Innovative Programsby Lilu Anderson 07.08.2024Discover how AI is shaping the future of education in local schools with new programs and tools aimed at enhancing ...
Treace Medical Concepts Sees 6% Revenue Boost in Q2 2024by Mark Eisenberg 07.08.2024Treace Medical Concepts reported a 6% rise in Q2 revenue to $44.5M, driven by new products and a growing surgeon ...
Southwest Gas Holdings Raises 2024 Net Income Guidance by $5 Millionby Mark Eisenberg 07.08.2024Southwest Gas Holdings Inc.'s Q2 earnings call highlights increased net income guidance, strategic initiatives, and strong financial position.
Rhythm Pharmaceuticals Reports Strong Q2 Results, Driven by IMCIVREEby Mark Eisenberg 07.08.2024Rhythm Pharmaceuticals sees robust Q2 2024 results with $29.1M revenues due to IMCIVREE's success in treating Bardet-Biedl syndrome.